Find Alpelisib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1217486-61-7, Byl-719, Byl719, Piqray, Nvp-byl719, Vijoice
Molecular Formula
C19H22F3N5O2S
Molecular Weight
441.5  g/mol
InChI Key
STUWGJZDJHPWGZ-LBPRGKRZSA-N
FDA UNII
08W5N2C97Q

Alpelisib
Alpelisib is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
1 2D Structure

Alpelisib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide
2.1.2 InChI
InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
2.1.3 InChI Key
STUWGJZDJHPWGZ-LBPRGKRZSA-N
2.1.4 Canonical SMILES
CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
2.1.5 Isomeric SMILES
CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
08W5N2C97Q
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Byl719

2. Nvp-byl719

3. Piqray

2.3.2 Depositor-Supplied Synonyms

1. 1217486-61-7

2. Byl-719

3. Byl719

4. Piqray

5. Nvp-byl719

6. Vijoice

7. Alpelisib (byl719)

8. (s)-n1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide

9. Byl 719

10. Chembl2396661

11. 08w5n2c97q

12. (2s)-n1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide

13. (2s)-1-n-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

14. (s)-pyrrolidine-1,2-dicarboxylic Acid 2-amide 1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-pyridin-4-yl)thiazol-2-yl)amide

15. 1,2-pyrrolidinedicarboxamide, N1-(4-methyl-5-(2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl)-2-thiazolyl)-, (2s)-

16. 1,2-pyrrolidinedicarboxamide, N1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-, (2s)-

17. Alpelisib [inn]

18. (2s)-n~1~-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide

19. (s)-n1-(4-methyl-5-(2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide.

20. Unii-08w5n2c97q

21. 4jps

22. 1lt

23. Alpelisib [usan]

24. Piqray (tn)

25. Alpelisib [jan]

26. Alpelisib [mi]

27. Alpelisib [usan:inn]

28. Alpelisib [who-dd]

29. Alpelisib (jan/usan/inn)

30. Gtpl7955

31. Schembl1911869

32. Alpelisib [orange Book]

33. Chebi:93752

34. Dtxsid70153355

35. Ex-a405

36. Byl 719; Byl719

37. Bdbm50436459

38. Mfcd22417085

39. Nsc765974

40. Nsc800065

41. S2814

42. Zinc68198368

43. Akos022186315

44. Ccg-269139

45. Cs-0663

46. Db12015

47. Nsc-765974

48. Nsc-800065

49. Ncgc00346717-03

50. Ncgc00346717-06

51. (2s)-n1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidine

52. 1217486-47-9

53. As-16349

54. Hy-15244

55. Sw220128-1

56. Cas:1217486-61-7;byl-719

57. D11011

58. A855666

59. J-004627

60. Q27074391

61. (2s)-n1-(4-methyl-5-(1-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl)-1,3-thiazol-2-yl)pyrrolidine-1,2-dicarboxamide

62. (2s)-n1-[4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide;alpelisib

2.4 Create Date
2012-03-05
3 Chemical and Physical Properties
Molecular Weight 441.5 g/mol
Molecular Formula C19H22F3N5O2S
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count4
Exact Mass441.14463062 g/mol
Monoisotopic Mass441.14463062 g/mol
Topological Polar Surface Area129 Ų
Heavy Atom Count30
Formal Charge0
Complexity663
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Alpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer. This cancer must be hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and PIK3CA mutated. The cancer must be detected by an FDA-approved test following progression on or after an endocrine-based regimen.


FDA Label


Treatment of breast cancer


Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5. 1).


Treatment of PIK3CA related overgrowth spectrum


Treatment of Fallopian tube carcinoma (excluding rhabdomyosarcoma and germ cell tumours), Treatment of ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours), Treatment of peritoneal carcinoma (excluding blastomas and sarcomas)


5 Pharmacology and Biochemistry
5.1 Pharmacology

Alpelisib does not prolong the QTcF interval. Patients taking alpelisib experience a dose dependent benefit from treatment with a 51% advantage of a 200mg daily dose over a 100mg dose and a 22% advantage of 300mg once daily over 150mg twice daily. This suggests patients requiring a lower dose may benefit from twice daily dosing.


5.2 ATC Code

L01XE


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EM - Phosphatidylinositol-3-kinase (pi3k) inhibitors

L01EM03 - Alpelisib


5.3 Absorption, Distribution and Excretion

Absorption

Alpelisib reached a peak concentration in plasma of 1320912ng/mL after 2 hours. Alpelisib has an AUClast of 11,1003760h ng/mL and an AUCINF of 11,1003770h ng/mL. A large, high fat meal increases the AUC by 73% and Cmax by 84% while a small, low fat meal increases the AUC by 77% and Cmax by 145%.


Route of Elimination

36% of an oral dose is eliminated as unchanged drug in the feces and 32% as the primary metabolite BZG791 in the feces. 2% of an oral dose is eliminated in the urine as unchanged drug and 7.1% as the primary metabolite BZG791. In total 81% of an oral dose is eliminated in the feces and 14% is eliminated in the urine.


Volume of Distribution

The apparent volume of distribution at steady state is 114L.


Clearance

The mean apparent oral clearance was 39.0L/h. The predicted clearance is 9.2L/hr under fed conditions.


5.4 Metabolism/Metabolites

Alpelisib is metabolized by hydrolysis reactions to form the primary metabolite. It is also metabolized by CYP3A4. The full metabolism of Alpelisib has yet to be determined but a series of reactions have been proposed. The main metabolic reaction is the substitution of an amine group on alpelisib for a hydroxyl group to form a metabolite known as M4 or BZG791. Alpelisib can also be glucuronidated to form the M1 and M12 metabolites.


5.5 Biological Half-Life

The mean half life of alprelisib is 8 to 9 hours.


5.6 Mechanism of Action

Phosphatidylinositol-3-kinase- (PI3K) is responsible for cell proliferation in response to growth factor-tyrosine kinase pathway activation. In some cancers PI3K's p110 catalytic subunit is mutated making it hyperactive. Alpelisib inhibits (PI3K), with the highest specificity for PI3K.


API SUPPLIERS

read-more
read-more

01

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI offers customized CDMO Solutions for API development and manufacturing services.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

02

Arevipharma

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

03

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

04

Shenzhen Tianyuan Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

05

Conscientia Industrial

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

06

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

ScinoPharm Taiwan, Ltd

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : TABLET;ORAL

Dosage Strength : 150MG

Packaging :

Approval Date : 2019-05-24

Application Number : 212526

Regulatory Info : RX

Registration Country : USA

blank

02

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : TABLET;ORAL

Dosage Strength : 200MG

Packaging :

Approval Date : 2019-05-24

Application Number : 212526

Regulatory Info : RX

Registration Country : USA

blank

03

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : VIJOICE

Dosage Form : TABLET;ORAL

Dosage Strength : 125MG

Packaging :

Approval Date : 2022-04-05

Application Number : 215039

Regulatory Info : RX

Registration Country : USA

blank

04

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : VIJOICE

Dosage Form : GRANULES;ORAL

Dosage Strength : 50MG/PACKET

Packaging :

Approval Date : 2024-04-24

Application Number : 218466

Regulatory Info : RX

Registration Country : USA

blank

05

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Film-Coated Tablets

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Filmtabl

Dosage Strength : 200mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

07

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Filmtabl

Dosage Strength : 200mg+50mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

08

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : TABLET

Dosage Strength : 200MG

Packaging :

Approval Date :

Application Number : 2497077

Regulatory Info :

Registration Country : Canada

blank

09

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : KIT

Dosage Strength : 50MG

Packaging :

Approval Date :

Application Number : 2497085

Regulatory Info :

Registration Country : Canada

blank

10

Country
Duphat
Not Confirmed
arrow

Country
arrow
Duphat
Not Confirmed

Alpelisib

Brand Name : PIVIKTO 150mg

Dosage Form : FCT

Dosage Strength : 150mg

Packaging : 56X1mg

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Film-Coated Tablets

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

02

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Film-Coated Tablets

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

03

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Filmtabl

Dosage Strength : 200mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

04

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Filmtabl

Dosage Strength : 200mg+50mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

05

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Alpelisibum

Brand Name : Piqray

Dosage Form : Filmtabl

Dosage Strength : 200mg+50mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : TABLET

Dosage Strength : 150MG

Packaging :

Approval Date :

Application Number : 2497069

Regulatory Info :

Registration Country : Canada

blank

02

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : TABLET

Dosage Strength : 200MG

Packaging :

Approval Date :

Application Number : 2497077

Regulatory Info :

Registration Country : Canada

blank

03

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : KIT

Dosage Strength : 50MG

Packaging :

Approval Date :

Application Number : 2497085

Regulatory Info :

Registration Country : Canada

blank

04

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

ALPELISIB

Brand Name : PIQRAY

Dosage Form : KIT

Dosage Strength : 200MG

Packaging :

Approval Date :

Application Number : 2497085

Regulatory Info :

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

read-more
read-more

01

Novartis South Africa (Pty) Ltd

Country
Duphat
Not Confirmed
arrow

Novartis South Africa (Pty) Ltd

Country
arrow
Duphat
Not Confirmed

Alpelisib

Brand Name : PIVIKTO 150mg

Dosage Form : FCT

Dosage Strength : 150mg

Packaging : 56X1mg

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank

02

Novartis South Africa (Pty) Ltd

Country
Duphat
Not Confirmed
arrow

Novartis South Africa (Pty) Ltd

Country
arrow
Duphat
Not Confirmed

Alpelisib

Brand Name : PIVIKTO 200mg

Dosage Form : FCT

Dosage Strength : 200mg

Packaging : 28X1mg

Approval Date :

Application Number :

Regulatory Info : Originator

Registration Country : South Africa

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Alpelisib Manufacturers

A Alpelisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alpelisib, including repackagers and relabelers. The FDA regulates Alpelisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alpelisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Alpelisib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Alpelisib Suppliers

A Alpelisib supplier is an individual or a company that provides Alpelisib active pharmaceutical ingredient (API) or Alpelisib finished formulations upon request. The Alpelisib suppliers may include Alpelisib API manufacturers, exporters, distributors and traders.

click here to find a list of Alpelisib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Alpelisib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Alpelisib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Alpelisib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Alpelisib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Alpelisib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Alpelisib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Alpelisib suppliers with NDC on PharmaCompass.

Alpelisib GMP

Alpelisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Alpelisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alpelisib GMP manufacturer or Alpelisib GMP API supplier for your needs.

Alpelisib CoA

A Alpelisib CoA (Certificate of Analysis) is a formal document that attests to Alpelisib's compliance with Alpelisib specifications and serves as a tool for batch-level quality control.

Alpelisib CoA mostly includes findings from lab analyses of a specific batch. For each Alpelisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Alpelisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Alpelisib EP), Alpelisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alpelisib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty